We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+0.14%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$204M
AUM Growth
+$15.9M
(+8.5%)
Cap. Flow
+$17.5M
Cap. Flow
% of AUM
8.58%
Top 10 Holdings %
Top 10 Hldgs %
6.14%
Holding
488
New
66
Increased
245
Reduced
135
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$976K |
| 2 |
Netflix
NFLX
|
+$953K |
| 3 |
CrowdStrike
CRWD
|
+$952K |
| 4 |
Royal Caribbean
RCL
|
+$905K |
| 5 |
TJX Companies
TJX
|
+$890K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$1.11M |
| 2 |
Eli Lilly
LLY
|
+$937K |
| 3 |
Freeport-McMoran
FCX
|
+$933K |
| 4 |
Align Technology
ALGN
|
+$933K |
| 5 |
Martin Marietta Materials
MLM
|
+$930K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 26.66% |
| 2 | Healthcare | 19.14% |
| 3 | Technology | 17.16% |
| 4 | Energy | 7.21% |
| 5 | Industrials | 6.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Cullinan Oncology
CGEM
$1.07B
| $72.4K | 0.04% |
4,153
-6,028
| -59% | -$128K |
|
427
Fulcrum Therapeutics
FULC
$249M
| $72K | 0.04% |
+11,606
| New | +$87.9K |
|
428
Recursion Pharmaceuticals
RXRX
$1.6B
| $71.9K | 0.04% |
9,590
+497
| +5% | +$4.33K |
|
429
Stoke Therapeutics
STOK
$1.83B
| $69.8K | 0.03% |
+5,167
| New | +$69.8K |
|
430
Arcturus Therapeutics
ARCT
$164M
| $69.8K | 0.03% |
2,865
-222
| -7% | -$6.73K |
|
431
Wave Life Sciences
WVE
$1.14B
| $69.7K | 0.03% |
+13,970
| New | +$79.7K |
|
|
AUTL
432
Autolus Therapeutics
AUTL
$389M
| $69.5K | 0.03% |
+19,984
| New | +$86.2K |
|
433
Sana Biotechnology
SANA
$913M
| $69.1K | 0.03% |
12,661
-9,053
| -42% | -$72.1K |
|
434
Structure Therapeutics
GPCR
$3.46B
| $68.8K | 0.03% |
1,753
+273
| +18% | +$11.2K |
|
435
Immunome
IMNM
$2.56B
| $68.3K | 0.03% |
+5,644
| New | +$88.3K |
|
436
Larimar Therapeutics
LRMR
$398M
| $67.7K | 0.03% |
+9,342
| New | +$71.5K |
|
437
Spyre Therapeutics
SYRE
$8.69B
| $65.8K | 0.03% |
2,797
-3,041
| -52% | -$103K |
|
438
ALX Oncology
ALXO
$272M
| $64.7K | 0.03% |
10,726
+4,160
| +63% | +$51.2K |
|
439
Prime Medicine
PRME
$544M
| $58.9K | 0.03% |
+11,459
| New | +$69.5K |
|
|
FLNA
440
Filana Therapeutics
FLNA
$43.5M
| $56.2K | 0.03% |
4,551
+1,672
| +58% | +$35.2K |
|
441
Cabaletta Bio
CABA
$444M
| $53.9K | 0.03% |
7,207
+2,992
| +71% | +$36.7K |
|
442
Lyell Immunopharma
LYEL
$318M
| $50.7K | 0.02% |
1,748
-397
| -19% | -$18.9K |
|
443
Taysha Gene Therapies
TSHA
$1.59B
| $48.6K | 0.02% |
+21,709
| New | +$63.2K |
|
444
Kyverna Therapeutics
KYTX
$481M
| $47K | 0.02% |
+6,269
| New | +$95.8K |
|
445
Zentalis Pharmaceuticals
ZNTL
$321M
| $38.9K | 0.02% |
9,509
+3,719
| +64% | +$41.5K |
|
446
Scilex Holding
SCLX
$49.4M
| $30.6K | 0.02% |
504
| – | – |
|
|
JBIO
447
Jade Biosciences
JBIO
$1.21B
| $6.11K | ﹤0.01% |
+105
| New | +$69.6K |
|
448
Apple
AAPL
$4.95T
| – | – |
-3,881
| Closed | -$666K |
|
449
Analog Devices
ADI
$181B
| – | – |
-3,761
| Closed | -$744K |
|
|
450
Align Technology
ALGN
$12B
| – | – |
-2,844
| Closed | -$933K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2024 Portfolio in Review
As of Q2 2024, Virtus ETF Advisers held 488 positions worth $204M, up 8.5% from $188M the previous quarter. Its ten largest holdings account for 6.1% of the portfolio.
Virtus ETF Advisers deployed $17.5M of net new capital in Q2 2024, opening 66 new positions and adding to 245 existing holdings. Its largest new stake was Qualcomm: 5,165 shares worth $1.03M.
By sector, the portfolio is most concentrated in Financials at 27% of assets, up from 20% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Extra Space Storage, an estimated $732K trimmed.
- Virtus ETF Advisers's largest Q2 2024 buy was Qualcomm: 5,165 shares worth $1.03M.
- Virtus ETF Advisers added most to EOG Resources in Q2 2024, an estimated $789K increase.
- Virtus ETF Advisers's biggest Q2 2024 reduction was Extra Space Storage, cutting an estimated $732K.
- Virtus ETF Advisers fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $1.11M.
- Virtus ETF Advisers's ten largest holdings make up 6.1% of its $204M portfolio in Q2 2024.
- Virtus ETF Advisers opened 66 new positions and closed 40 in Q2 2024.
- Virtus ETF Advisers's portfolio value rose 8.5% quarter-over-quarter to $204M.
Based on Virtus ETF Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.